Today, the President & CEO of Novavax (NASDAQ: NVAX), Stanley Erck, bought shares of NVAX for $164K.
This recent transaction increases Stanley Erck’s holding in the company by 43.81% to a total of $554.8K. In addition to Stanley Erck, 2 other NVAX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Novavax’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $9.65 million and GAAP net loss of $46.35 million. In comparison, last year the company earned revenue of $5.68 million and had a GAAP net loss of $43.85 million. Currently, Novavax has an average volume of 3.83M.
Based on 8 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $4.33, reflecting a -61.0% downside. Eight different firms, including B.Riley FBR and Cantor Fitzgerald, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza, and Ebola virus.
Read More on NVAX:
